Bohuslav Melichar

44.4k total citations · 8 hit papers
503 papers, 13.2k citations indexed

About

Bohuslav Melichar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bohuslav Melichar has authored 503 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 254 papers in Oncology, 240 papers in Pulmonary and Respiratory Medicine and 131 papers in Molecular Biology. Recurrent topics in Bohuslav Melichar's work include Renal cell carcinoma treatment (105 papers), Cancer Immunotherapy and Biomarkers (61 papers) and Cancer Genomics and Diagnostics (57 papers). Bohuslav Melichar is often cited by papers focused on Renal cell carcinoma treatment (105 papers), Cancer Immunotherapy and Biomarkers (61 papers) and Cancer Genomics and Diagnostics (57 papers). Bohuslav Melichar collaborates with scholars based in Czechia, United States and France. Bohuslav Melichar's co-authors include Alain Ravaud, Bernard Escudier, Sergio Bracarda, Emilio Bajetta, Dagmar Solichová, Ralph S. Freedman, Cezary Szczylik, A Płużańska, Christine Chevreau and P. Koralewski and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Bohuslav Melichar

477 papers receiving 13.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

2015 688 citations Bohuslav Melichar et al. profile →
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

2010 632 citations Bernard Escudier, Emilio Bajetta et al. profile →
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

2020 498 citations Bohuslav Melichar, Jens Bedke et al. profile →
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

2023 432 citations Funda Meric‐Bernstam, Vicky Makker et al. profile →
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013 383 citations Bohuslav Melichar et al. profile →
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

2019 377 citations Aristotelis Bamias, Bohuslav Melichar et al. profile →
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

2021 244 citations Bohuslav Melichar et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Bohuslav Melichar

Since Specialization

Citations

This map shows the geographic impact of Bohuslav Melichar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bohuslav Melichar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bohuslav Melichar more than expected).

Fields of papers citing papers by Bohuslav Melichar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bohuslav Melichar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bohuslav Melichar. The network helps show where Bohuslav Melichar may publish in the future.

Co-authorship network of co-authors of Bohuslav Melichar

This figure shows the co-authorship network connecting the top 25 collaborators of Bohuslav Melichar. A scholar is included among the top collaborators of Bohuslav Melichar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bohuslav Melichar. Bohuslav Melichar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study 2025 ·European Journal of Cancer ·Viktor Grünwald, Axel Bex, Sylvie Rottey, (unknown), Giuseppe Procopio, Guillermo Velasco, Bohuslav Melichar, Jens Bedke, Lisa Pickering, (unknown), Manuela Schmidinger, Aristotelis Bamias, Marine Gross‐Goupil, Camillo Porta, Philippe Barthélémy, (unknown), Laurence Albigès	1
2	The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer 2024 ·Current Oncology ·(unknown), Bohuslav Melichar, Igor Sirák, J Vaňásek, Jiřı́ Petera, (unknown), (unknown), (unknown), Zuzana Šinkorová, Milan Vošmik	5
3	LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study 2023 ·Annals of Oncology ·Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, D-Y. Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yanhui Ma, Soham D. Puvvada, J-Y. Lee	3
4	Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial 2022 ·Journal for ImmunoTherapy of Cancer ·Lukáš Rob, David Cibula, Paweł Knapp, Peter Mallmann, Jaroslav Klát, Luboš Minář, Pavel Bartoš, Josef Chovanec, (unknown), Marek Pluta, (unknown), Jiří Špaček, Bohuslav Melichar, (unknown), Jitka Fučíková, Tereza Hrnčiarová, Roman Korolkiewicz, (unknown), Jiřina Bartůňková, Radek Špíšek	31
5	Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients 2020 ·SHILAP Revista de lepidopterología ·Alena Novakova-Jiresova, Kateřina Kopečková, Ludmila Boublíková, (unknown), Bohuslav Melichar, Luboš Petruželka, Jindřich Fínek, Ondřej Fiala, (unknown), (unknown), Zdeněk Linke, (unknown), Jana Prausová, Tomáš Büchler	1
6	Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice 2020 ·Targeted Oncology ·Tomáš Büchler, Igor Kišš, (unknown), Ondřej Fiala, (unknown), Michal Svoboda, (unknown), Kateřina Kopečková, Alexandr Poprach, Jindřich Fínek, Luboš Petruželka, Bohuslav Melichar	2
7	<p>Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients</p> 2020 ·Cancer Management and Research ·Alena Novakova-Jiresova, Kateřina Kopečková, Ludmila Boublíková, (unknown), Bohuslav Melichar, Luboš Petruželka, Jindřich Fínek, Ondřej Fiala, (unknown), (unknown), Zdeněk Linke, Igor Kišš, Jana Prausová, Tomáš Büchler	9
8	Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database 2019 ·Urologic Oncology Seminars and Original Investigations ·Alexandr Poprach, (unknown), Radek Lakomý, (unknown), Michal Staník, (unknown), Igor Kišš, Ondřej Slabý, Hana Študentová, Bohuslav Melichar, Jaroslav Juráček, Ondřej Fiala, Jindřich Kopecký, Kateřina Kopečková, Milada Zemanová, Tomáš Büchler	5
9	HPV Status and Mutation Analysis Using Multiparallel Sequencing in Distal Oesophageal and Gastro-oesophageal Junction Adenocarcinomas 2018 ·Folia Biologica ·Milan Vošmik, Hana Vošmiková, (unknown), Igor Sirák, Ján Laco, Aleš Ryška, Jiřı́ Petera, Bohuslav Melichar, Renata Soumarová	0
10	Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis 2018 ·Cancer Management and Research ·Tomáš Büchler, (unknown), Alexandr Poprach, Ondřej Fiala, Igor Kišš, Kateřina Kopečková, Ladislav Dušek, Veronika Veškrňová, (unknown), (unknown), Jindřich Fínek, Marek Svoboda, Luboš Petruželka, Bohuslav Melichar	8
11	Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice 2016 ·Drugs & Aging ·(unknown), Alexandr Poprach, Radek Lakomý, Zbyněk Bortlíček, Bohuslav Melichar, Tomáš Pavlík, Ondřej Slabý, Rostislav Vyzula, Marek Svoboda, Igor Kišš, Hana Študentová, Milada Zemanová, Ondřej Fiala, Kateřina Kubáčková, Ladislav Dušek, (unknown), Tomáš Büchler	15
12	Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency 2015 ·European Journal of Cancer ·Alexandr Poprach, Zbyněk Bortlíček, Bohuslav Melichar, Radek Lakomý, Marek Svoboda, Igor Kišš, Milada Zemanová, Ondřej Fiala, Kateřina Kubáčková, Oldřich Coufal, Tomáš Pavlík, Ladislav Dušek, Rostislav Vyzula, Tomáš Büchler	10
13	Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry 2014 ·Targeted Oncology ·(unknown), Kateřina Kubáčková, Zbyněk Bortlíček, Tomáš Pavlík, Bohuslav Melichar, Zdeněk Linke, Petra Pokorná, Rostislav Vyzula, Jana Prausová, Tomáš Büchler	6
14	Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis 2014 ·Urologic Oncology Seminars and Original Investigations ·Tomáš Büchler, Zbyněk Bortlíček, Alexandr Poprach, Kateřina Kubáčková, Igor Kišš, Milada Zemanová, Ondřej Fiala, Ladislav Dušek, Rostislav Vyzula, Bohuslav Melichar	12
15	Urinary Neopterin, Serum Retinol, α-tocopherol and Homocysteine in Breast Cancer Patients During Treatment with Bevacizumab and Chemotherapy 2010 ·Pteridines ·Bohuslav Melichar, Hana Kalábová, Lenka Kujovská Krčmová, (unknown), (unknown), Radomı́r Hyšpler, Hana Študentová, (unknown), Petra Holečková, M Pecka, Dagmar Solichová	1
16	Serum Neopterin in Patients with Malignant Melanoma 2009 ·Pteridines ·Petr Beneš, Bohuslav Melichar, Hana Študentová, (unknown), Eva Malířová, (unknown), (unknown), Karel Cwiertka	1
17	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial breakdown → 2007 ·The Lancet ·Bernard Escudier, A Płużańska, P. Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, Bohuslav Melichar, Emilio Bajetta, В. А. Горбунова, Jacques‐Olivier Bay, I. Bodrogi, Agnieszka Jagiełło-Gruszfeld, N. Moore	1722
18	Urinary Neopterin in Patients with upper Gastrointestinal, Biliary and Pancreatic Carcinomas 2006 ·Pteridines ·Bohuslav Melichar, Dagmar Solichová, (unknown), Lubor Urbánek, (unknown)	10
19	Serum Neopterin and Angiotensin-converting Enzyme In Cancer Patients 1994 ·Pteridines ·Bohuslav Melichar, Pavel Jandík, J Vávrová, (unknown), Eva Malířová, Z Voboril	1
20	Are Disturbances of Zinc Metabolism in Human Immunodeficiency Virus Type I (HIV-I) Infection Caused By Immune Activation? 1993 ·Pteridines ·Bohuslav Melichar, Robert Zangerle, Erika Artner‐Dworzak, H. Wächter, Dietmar Fuchs	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact